KATP channel openers: Tissue selectivity of original 3-alkylaminopyrido- and 3-alkylaminobenzothiadiazine 1,1-dioxides

Biochemical Pharmacology

Volumn 75, Issue 2, 2008, Pages 468-475

  Lebrun, Philippe ^a   Becker, Bénédicte ^a   Morel, Nicole ^b   Ghisdal, Philippe ^b   Antoine, Marie Hélène ^a   de Tullio, Pascal ^c   Pirotte, Bernard ^c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

ATP sensitive K+ channel; Benzothiadiazine dioxides; Insulin secreting cell; KATP channel openers; Pyridothiadiazine dioxides; Vascular smooth muscle

Indexed keywords

3 ALKYLAMINOBENZOTHIADIAZINE 1,1 DIOXIDE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); DIAZOXIDE; HETEROCYCLIC COMPOUND; PINACIDIL; POTASSIUM 42; RUBIDIUM 86; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLIBENCLAMIDE; INSULIN; THIADIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CELL ACTIVATION; CELL SELECTION; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; HEART FUNCTION TEST; HEART MUSCLE TENSION; IC 50; INSULIN RELEASE; ISOTOPE LABELING; MUSCLE RELAXATION; NONHUMAN; PANCREAS BLOOD FLOW; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION LINE; VASCULAR RING; VASODILATATION; ANIMAL; ANTIBODY SPECIFICITY; CELL MEMBRANE POTENTIAL; IN VITRO STUDY; PHYSIOLOGY; SECRETION; VASOCONSTRICTION; WISTAR RAT;

ANIMALS; AORTA; GLYBURIDE; INSULIN; KATP CHANNELS; MEMBRANE POTENTIALS; ORGAN SPECIFICITY; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZINES; VASOCONSTRICTION;

EID: 37349016003     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.032     Document Type: Article

References (37)

1. + channels. Prog Biophys Mol Biol 81 (2003) 133-176
2. Aguilar-Bryan L., and Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocrine Rev 20 (1999) 101-135
3. ATP channels. Physiol Rev 78 (1998) 227-245
4. + channels and insulin secretion: their role in health and disease. Diabetologia 42 (1999) 903-919
5. ATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol 29 (2002) 312-316
6. Quayle J.M., Nelson M.T., and Standen N.B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77 (1997) 1165-1232
7. IR 6.2/SUR 1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem 13 (2006) 361-376
8. ATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 24 (2004) 213-266
9. ATP channel openers. Curr Top Med Chem 6 (2006) 1031-1047
10. Robertson D.W., and Steinberg M.I. Potassium channel modulators: scientific applications and therapeutic promise. J Med Chem 33 (1990) 1529-1541
11. + channels as therapeutic drug targets. Pharmacol Ther 94 (2002) 157-182
12. Pirotte B., de Tullio P., Antoine M.-H., Sebille S., Florence X., and Lebrun P. New insights in the development of ATP-sensitive potassium channel openers. Exp Opin Ther Pat 15 (2005) 497-504
13. Pirotte B., Fontaine J., and Lebrun P. Recent advances in the chemistry of potassium channel openers. Curr Med Chem 2 (1995) 573-582
14. ATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1.1-dioxides. J Med Chem. 46 (2003) 3342-3353
15. de Tullio P., Pirotte B., Lebrun P., Fontaine J., Dupont L., Antoine M.-H., et al. 3- and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships. J Med Chem 39 (1996) 937-948
16. + channels and inhibiting insulin release. Diabetologia 43 (2000) 723-732
17. Pirotte B., de Tullio P., Lebrun P., Antoine M.-H., Fontaine J., Masereel B., et al. 3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1.1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: A new class of potassium channel openers?. J Med Chem 36 (1993) 3211-3213
18. Pirotte B., Ouedraogo R., de Tullio P., Khelili S., Somers F., Boverie S., et al. 3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis and pharmacological evaluation. J Med Chem 43 (2000) 1456-1466
19. Antoine M.-H., Berkenboom G., Fang Z.Y., Fontaine J., Herchuelz A., and Lebrun P. Mechanical and ionic response of rat aorta to diazoxide. Eur J Pharmacol 216 (1992) 299-306
20. 86Rb fluxes and contractile activity in the rat aorta. Pharmacology 41 (1990) 36-48
21. + channels in endocrine and smooth muscle tissues. Br J Pharmacol 134 (2001) 375-385
22. Ghisdal P., Gomez J.P., and Morel N. Action of a NO donor on the excitation-contraction pathway activated by noradrenaline in rat superior mesenteric artery. J Physiol 522 (2000) 83-96
23. Aschcroft F.M., and Rorsman P. Electrophysiology of the pancreatic β-cell. Prog Biophys Mol Biol 54 (1989) 87-143
24. Malaisse W.J., and Lebrun P. Mechanisms of sulfonylurea-induced insulin release. Diab Care 13 Suppl. 3 (1990) 9-17
25. + channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. J Pharmacol Exp Ther 250 (1989) 261-271
26. Antoine M.-H., Pirotte B., Hermann M., de Tullio P., Delarge J., Herchuelz A., et al. Cationic and secretory effects of BPDZ 44 and diazoxide in rat pancreatic islets. Experientia 50 (1994) 830-832
27. Cosgrove K.E., Antoine M.-H., Lee A.T., Barnes P.D., de Tullio P., Clayton P., et al. BPDZ154 activates adenosine 5'-triphosphate-sensitive potassium channels: In vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism. J Clin Endocrinol Metab 87 (2002) 4860-4868
28. IR6.2/SUR1 channel opener. Diabetes 51 (2002) 1896-1906
29. de Tullio P., Boverie S., Becker B., Antoine M.-H., Nguyen Q.-A., Francotte P., et al. 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6.7-disubstitution on potency and tissue selectivity. J Med Chem 48 (2005) 4990-5000
30. + channels and inhibition of insulin release: effect of BPDZ 62. J. Pharmacol Exp Ther 277 (1996) 156-162
31. + channels. Biochem Pharmacol 47 (1994) 1381-1386
32. de Tullio P., Lebrun P., Florence X., Antoine M.H., Francotte P., and Pirotte B. Selective pancreatic ATP-sensitive potassium channel openers for the treatment of glucose homeostasis disorders. Drugs Fut 31 (2006) 991-1001
33. Nielsen F.E., Bodvarsdottir T.B., Worsaae A., McKay P., and Stidsen C.E. Boonen HCM et al.6-chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1.1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic β-cells. J Med Chem 45 (2002) 4171-4187
34. Nielsen F.E., Ebdrup S., Frost Jensen A., Ynddal L., Bodvarsdottir T.B., Stidsen C., et al. New 3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1.1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells. J Med Chem 49 (2006) 4127-4139
35. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384 (1996) 644-648
36. + elicited by cromakalim (BRL 34915) in tonic and phasic vascular tissue. Naunyn Schmiedeberg's Arch Pharmacol 338 (1998) 319-326
37. Edwards G., and Weston A.H. The pharmacology of ATP-sensitive potassium channels. Ann Rev Pharmacol Toxicol 33 (1993) 597-637